Background: Hepatitis B virus and Hepatitis C virus infection is one of the public health problems in Egypt. So we aimed to evaluate the efficacy of serum osteopontin as predictor of hepatic fibrosis regression and virological response in patients with chronic HBV or HCV infection. Methods: This study has been conducted on 74 HBeAg + ve chronic HBV infection, 74 chronic HCV infection and 74 healthy controls. HBV patients treated with Entecavir. HCV patients treated with sofosbuvir, daclatasvir with or without ribavirin. One year post HBeAg seroconversion and 3 months after end of regular antiviral treatment for patients with chronic HBV and chronic HCV infection respectively, hepatic condition was reevaluated. Results: 14.9% of patients with HBV, failed to achieve undetectable HBV DNA or HBeAg seroconversion and 2.7% of patients with HCV infection, failed to achieve SVR. In chronic HBV, pretreatment high serum osteopontin predict failure of virological response and hepatic fibrosis regression at a cutoff > 115.5, with 90.91% sensitivity, 82.54% specificity. Also high degree of liver stiffness predicts failure of hepatic fibrosis regression at a cutoff > 8.7, with 81.8% sensitivity, 73% specificity. Conclusions: In chronic HBV infection low osteopontin predicts good virological response and hepatic fibrosis regression. But it has no role in predicting SVR or hepatic fibrosis regression in chronic HCV infected patients.
Introduction
Egypt has the highest prevalence of hepatitis C virus (HCV) infection worldwide [1] .
Chronic hepatitis C virus infection is the main cause of end-stage liver disease with liver cirrhosis and hepatocellular carcinoma in Egypt, it's responsible for chronic hepatitis in about 80% of the infected patients, of them about 20% develop liver cirrhosis of them about 6% develop decompensated liver disease and 5% of the patients with liver cirrhosis develop hepatocellular carcinoma [2] .
Sofosbuvir, daclatasvir, with or without ribavirin combination are safe and effective in treatment of chronic hepatitis C virus infection in Egypt [3] .
Sustained virological response after 3 months of regular treatment achieved in about 95% of patients in the easy-to-treat group who received Sofosbuvir and daclatasvir, and reach about 92% in the difficult-to-treat group who treated with Sofosbuvir, daclatasvir, and ribavirin [3] .
Direct acting antiviral (DAA) combinations proved to cause obvious improvements in hepatic laboratory parameters with good clinical outcomes in chronic hepatitis C virus treated patients [4] .
The side effects reported post treatment with sofosbuvir, daclatasvir, and ribavirin combination range from mild adverse events as anemia, fatigue, headache, and itching to severe side effects as hepatocellular carcinoma and hepatic encephalopathy which reported in patients with advanced liver disease [5] .
Hepatitis B virus (HBV) infection is one of the public health problems in
Egypt [6] .
About 350 million patients in Egypt have chronic hepatitis B virus infection and more than 1 million die from liver cirrhosis and hepatocellular carcinoma annually [7] .
The aim of therapy of patients with chronic hepatitis B virus infection is to preventthe liver disease progression by suppressing hepatitis B virus DNA replication [8] .
The available oral antiviral drugs for treatment of chronic HBV infected patients include nucleos(t)ide analogue as lamivudine, adefovir, entecavir, telbivudine and tenofovir [9] .
Effective antiviral treatment of chronic hepatitis B virus infection reduced the risk of long-term complications and improved patient survival [9] .
Entecavir is a cyclopentyl guanosine analogue with a potent inhibitory effect on HBV DNA replication [10] .
Entecavir is effective in the treatment of patients with either HBeAg positive or HBeAg negative chronic hepatitis B [11] .
Treatment with Entecavir cause viral suppression with significant improvement in hepatic fibrosis and liver functions biochemical parameters [12] .
Osteopontin, is a secreted Phosphoprotein involved in different hepatic pathological conditions such as inflammation, immunity, angiogenesis, liver fibrosis progression, invasion and metastasis of HCC [13] . In the liver, Osteopontin exists normally in the epithelial bile duct [14] .
Osteopontin pathologically expressed in Kupffer cells, hepatic macrophages and hepatic stellate cells in areas of liver necrosis [15] .
Osteopontin has a role in many liver diseases as acute liver cell failure [16] , nonalcoholic fatty liver diseases [17] , alcoholic liver diseases [18] , hepatic fibrosis with chronic hepatitis B [19] , and chronic hepatitis C [20] . Also, Osteopontin considered as a better prognostic marker for early hepatocellular carcinoma compared with alpha-fetoprotein [21] .
Hepatic fibrosis is the most dangerous complication of chronic hepatic disease that finally leads to cirrhosis with subsequent complications [22] .
So, in this study we try to evaluate the effect of antiviral treatment in decreasing serum Osteopontin level as a marker of improving hepatic fibrosis and as a pretreatment marker to predict response to treatment in patients with chronic hepatitis B or chronic hepatitis C virus infection.
Aim of the Work
The current study aimed to evaluate the effect of antiviral treatment in decreasing serum Osteopontin level as a marker of improving hepatic fibrosis and as a pretreatment marker to predict response to treatment in patients with chronic hepatitis B or chronic hepatitis C virus infection. were excluded from the study as they were out of the treatment protocol. 
Patients and Methods

Laboratory Workup
The Laboratory Tests
1) The platelet count was done by Celtak haematology analyzer (Nihon Kohden, Japan).
2) The liver function tests including (total and direct bilirubin, serum albumin, AST and ALT) were done by BT 1500 full automated chemistry analyzer (Bioticnica, Italy).
3) The prothrombin time, prothrombin concentration and INR was done using Thromborel S kits (Siemens, Germany) using BE coagulator (Germany). Probability (p-value) p-value < 0.05 was considered significant.
4) HBV-DNA was done by StepOnePlus
p-value < 0.001 was considered as highly significant.
p-value > 0.05 was considered insignificant.
Results
The present study included 222 subject classified to 3 groups, the first group include 74 apparent healthy control, the second group include 74 naive chronic HBV infected patient with their mean ages were 50. 4 antiviral therapy with sofosbuvir 400 mg and daclatasvir 60 mg with or without weigh-based ribavirin (800 -1200 mg) once daily.
By comparing laboratory data and liver stiffness before and after therapy in patients with chronic hepatitis C virus infection, there was statistically significant difference (p-value < 0.05) between (Bilirubin and Platelets) and there was highly statistical significant difference (p-value < 0.001) between (AST, ALT, Liver stiffness and osteopontin) before and after therapy.
In patients with chronic hepatitis B virus infection, there were statistically significant difference (p-value < 0.05) between (liver stiffness and Platelets) before and after therapy while there was highly statistical significant difference (p-value < 0.001) between (AST, ALT, Bilirubin, viral load and osteopontin) before and after therapy ( Table 2 ).
In patients with chronic HCV no statistical significant difference (p-value > 0.05) between responders and non-responders to therapy as regard laboratory data and liver stiffness before therapy.
In patients with chronic hepatitis B virus infection, by comparing between responders and non-responders to therapy as regard pretreatment laboratory data (AST, Bilirubin, Albumin, Platelets, viral load and liver stiffness) showed Figure 1 & Figure 2 ).
However, in patients with chronic hepatitis C no role of pretreatment serum osteopontin to predict post treatment SVR or improvement in hepatic fibrosis.
Discussion
In humans Osteopontin is located on chromosome number 4, region 22 and it's composed of about 300 amino acids [25] .
Osteopontin secretion is a marker to predict hepatic fibrosis in patients with hepatitis B virus or hepatitis C virus infection [26] . [29] .
In this study we found no role of any pretreatment liver function laboratory parameters, platelet count, liver stiffness or serum Osteopontin as predictor of post treatment response treatment.
With our study, Mousa et al., 2017 found that no role of pretreatment HCV RNA in prediction of end treatment response or sustained virologic responses [30] .
In contrast to our study Ahmed osteopontin may directly promote HCV replication [35] .
Also study done by Iqbal et al., 2013 demonstrated that, HCV-induced osteopontin activation [36] .
In our study we have significant higher level of pretreatment serum osteopontin in non-responder patients compared with responder one. Also we found that low pretreatment serum osteopontin has a high efficacy in predicting post treatment hepatic fibrosis regression and effective virologicl response to entecavir antiviral therapy with undetectable HBV-DNA and HBeAg seroconversion in patients with chronic hepatitis B virus infection at a cutoff level of <115.5 ng/ml, with high sensitivity and specificity.
This come in agreement with Liu et al., 2017 who reported that low serum osteopontin may be a predictor of good prognosis in patients with chronic hepatitis B virus infection but high serum osteopontin directly correlate with liver cell injury [37] .
In this study we also found that pretreatment low degree of hepatic fibrosis is a good marker that predicts post treatment hepatic fibrosis regression in chronic hepatitis B virus infected patients at a cutoff level of <8.7, but with lower sensitivity and specificity compared to serum osteopontin.
This come in agreement with Chon et al. 2017 who concluded that low pre-Open Journal of Gastroenterology treatment liver stiffness value (<12.0 kPa) was a significant predictor of fibrosis improvement in patients with chronic hepatitis B virus infection [38] .
In conclusion: pretreatment low serum osteopontin in addition to early hepatic fibrosis were predictor of good prognosis in patients with chronic HBV infection with good virological response and hepatic fibrosis regression. Although, pretreatment serum osteopontin level was higher in chronic hepatitis C virus infected patients than post treatment one. But it had no role in predicting post treatment SVR or hepatic fibrosis regression. Further studies on large number of patients are needed to evaluate its role as prognostic marker in chronic hepatitis C virus infected patients.
